T-Cure BioScience, Inc. news
LOS ANGELES, CA – October 6, 2022 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors, today announced that the National Cancer Institute (NCI) and Rutgers University sites are open to recruit patients for the treatment of Kita-Kyushu lung cancer antigen 1 (KK-LC-1) expressing malignancies, including gastric, lung, cervical and triple negative breast cancers. The investigator-initiated p
LOS ANGELES, CA, USA October 5, 2021 T-Cure Bioscience, Inc., a privately held company focused on developing autologous T Cell Receptor Therapy (TCR-T) products for the treatment of solid tumors, and Atlas Antibodies AB, a Swedish company commercializing PrecisA monoclonal antibodies (mAb) for oncology targets, announced today a collaborative agreement for the development, manufacture, and supply of CT83 (KK-LC-1) mAb. These will be used to develop a diagnostic test to identify tumors
Sherman Oaks, CA – March 17, 2021 – T-Cure Bioscience, Inc., a privately held company focused on developing T cell receptor (TCR) therapy products for the treatment of solid tumors,
- Immunotech Biopharm Ltd will have rights to develop and commercialize 800TCR, a HERV-E targeting T cell receptor (TCR) therapy for the treatment of kidney cancer, in China
- T- Cure Bioscience to receive an upfront payment and future development milestones and royalties
Sherman Oaks, CA – January 20, 2021 – T-Cure Bioscience, Inc., a privately he